Pluristem Therapeutics (NASDAQ:PSTI) has dosed three patients in two different hospitals in Israel under a compassionate use program for the treatment of COVID-19.
Additional patients in Israel are expected to be enrolled in coming days. All three treated patients are in a high-risk group.
Pluristem is prepared for immediate ramp-up of PLX
cell production with consistent batch-to-batch cell production quality
through its GMP certified manufacturing facilities in order to meet
potential demand.
The company is in discussions with regulators in the U.S. and Europe to define its clinical strategy for COVID-19.
Shares are up 11% premarket.
https://seekingalpha.com/news/3556218-pluristem-treats-first-three-covidminus-19-patients-in-israel-shares-up-11-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.